Indian pharma may have had its share of troubles in 2013, but amidst the gloom, the industry's poster boys who will be watched out for very carefully in 2014.
Shanghvi: 'Sun' is shining!
Sun Pharma's Dilip Shanghvi tops the chart. If 2013 saw Sun Pharma's market cap zoom 54 percent, and Dilip Shanghvi rise to be rated the third richest man in the country, 2014 will challenge him to sustain growth in India and the overseas markets. And this is where his knack for acquisition targets should come into play. Everyone will keenly watch out for Shanghvi's inorganic moves.
Dr Reddy's: Work cut out
GV Prasad Reddy and Satish Reddy of Dr Reddy's Labs have a big task at hand - large business restructuring process, reorientation of operations and increasing focus on global markets. Keep an eye on the men at the helm of DRL for their domestic strategies to beat the pricing blues and inorganic moves in the overseas market.
Lupin: New Boss, New Hope
Nilesh Gupta, the newly crowned CEO of Lupin has a lot to prove. Lupin's market cap grew 48 percent on the back of a solid US business, key branded product opportunities and alliances in 2013, but this year Japan will be crucial to his plans.
Aurobindo Executives: Dark Horses
The dark horses are Aurobindo Pharma's Arvind Vasudeva and N Govindrajan. They quietly led the company to more than double its market cap in 2013. With a sharp focus on product development and business in the US markets, Aurobindo Pharma will be a key company investors will look out for.
Tiding through USFDA Troubles
Lastly, amidst this Ranbaxy's Arun Shawney and the Khorakiwala's of the Wockhardt will continue to be on the radar of investors who will monitor their progress and performance in resolving the critical regulatory challenges.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
